Two Massachusetts biotech startups working on potential cancer treatments said Friday that they have made deals to collaborate with Celgene (CELG), the drug maker being acquired in one of the biggest pharmaceutical mergers ever.

Kyn Therapeutics, a Boston biotech, said it has signed an agreement with Celgene to develop immuno-oncology medicines. Kyn will receive an upfront cash payment of $80 million and an equity investment from Celgene, which will get exclusive options to license two drug development programs. Kyn is eligible for additional payments if it reaches specified goals for developing and marketing new medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy